To the Editor: The availability of replacement factor products and improvements in treatment strategies over time have led to increased life expectancy of patients with hemophilia; consequently, the incidence of age-related comorbidities has increased in this population [1,2]. There have been conflicting published data regarding the risks of cardiovascular (CV) comorbidities in patients with he...

Hemophilia A and B patients seen at nine US regional treatment centers were tested for serologic markers of hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatitis delta virus (HDV) during 1987 and 1988. Because human immunodeficiency virus (HIV) infection, a potentially confounding variable, was present in 53% of the group, the population was divided by HIV status for analysis purposes...

inhibitor development is a lifelong challenge for patients with bleeding disorders who received replacement therapy. most commonly, inhibitor formation was observed in hemophilia a patients but patients with rare bleeding disorders (rbd) especially patients with deficiency of factor xiii (fxiii) and factor v (fv) can develop an inhibitor against exogenous factors. several factors considered as ...

Hepatic histologic materials (biopsy or autopsy) and associated clinical data from 1 55 hemophiliacs were collected by an ad hoc hemophilia study group and analyzed retrospectively in an effort to determine the spectrum of liver disease in this population and to examine the relationship between the severity of liver disease and treatment history. Clinical information on the frequency of complic...

Plasminogen activator inhibitor-1 (PAI-1) deficiency causes a rare bleeding disorder by allowing excessive fibrinolysis to occur. Knowledge of the specific type and severity of the bleeding disorder is crucial in planning a safe and appropriate treatment sequence in conjunction with a hemophilia team. This article reports the oral management of a 9-year-old female with PAI-1 inhibitor deficienc...

D ESPITE CONSIDERABLE advances in the treatment of hemophilia, clinical expertise in hemophilia care is often concentrated within hemophilia treatment centers. These centers directly and indirectly care for most patients with hemophilia, and provide sophisticated services to this patient population. Much as bone marrow transplantation (BMT) and transfusion medicine have earned a special niche i...

background: hemophilia b is an x-linked recessive coagulation disorder caused by factor ix deficiency.  analysis of factor ix gene polymorphisms is considered the best approach for prenatal diagnosis and carrier detection of hemophilia b where the identification of gene mutation is not easily possible.   objective: to study the frequency of three factor ix-linked restriction fragment length pol...

development of inhibitor to factor viii is the most serious complication of hemophilia therapy. to determine the prevalence of inhibitors in iran hemophilia a patients exposed to blood products, 1280 hemophilia a patients (age range 9 months-84 years) were evaluated. all patients received several blood products such as fresh frozen plasma (ffp), cryoprecipitate, and factor viii. 635 of 1280 pat...

OBJECTIVE To examine the direct and indirect costs of hemophilia care among persons with hemophilia A in the US. METHODS Observational data were obtained from HUGS-Va, a multi-center study from six federally supported hemophilia treatment centers (HTCs). Eligible individuals completed a standardized initial questionnaire and were followed regularly for 2 years to obtain information on work or...